Drug intelligence / Profile preview

olibatinib

Development stage: Preclinical
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration: Oral

Overview

Olibatinib is a small molecule tyrosine kinase inhibitor developed for the treatment of certain cancers, particularly chronic myeloid leukemia (CML). It is designed to target and inhibit the BCR-ABL tyrosine kinase, which plays a key role in the pathogenesis of CML. By blocking this abnormal protein, olibatinib aims to slow or stop the proliferation of cancer cells. The drug may also have activity against other kinases involved in hematologic malignancies. Olibatinib is under clinical investigation and has not yet received regulatory approval.

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on olibatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olibatinib.

Explore the full profile